https://www.selleckchem.com/products/jke-1674.html
017), advanced clinical stage (P=0.031), positive lymph node metastasis (LNM) (P=0.009), and high Ki-67 index (P=0.023). Lower expression was recognized as an impact factor for metastasis-free survival (MFS) in BC. Lower levels of could promote BC cell proliferation and migration, and are associated with advanced BC. There is potential for as a marker to assist the selection of new BC treatment. Lower levels of DTX1 could promote BC cell proliferation and migration, and are associated with advanced BC. There is potential for DTX1 as a
Like
Comment
Share
